Table 3 Differences in coagulation tests, thromboelastography parameters and disease severity scores for 30-day survivors and non-survivors

D-dimer, mg/L (IQR)

< 0.25

0.80 (0.5–2.46)

0.93 (0.7–1.77)

0.82 (0.44–3.1)

0.79 (0.47–2.17)

0.88

0.94

Fibrinogen, g/L (IQR)

2–4

5 (5–5)^b

4.95 (4.5–5)

5 (5–5)^b

5 (5–5)^b

1.00

1.00

Prothrombin time^a, s (IQR)

11–12.5

13.45 (12.9–13.8)

12.8 (12.5–13.9)

14 (12.8–15)

14 (13.4–14.7)

0.36

0.12

Activated partial thromboplastin time, s (IQR)

25.1–36.5

29.7 (28.9–32.6)

26.45 (22.4–28.6)

28.8 (27.2–32.7)

32.5 (27.8–54.4)

0.45

< 0.01

Platelet count, X10⁹/L (IQR)

171–388

348.5 (223–418)

342.5 (209–444)

316 (261–429)

348 (208–458)

334 (311–432)

291 (271–334)

0.76

0.50

0.39

HMA, mm (IQR)

52–68

71.3 (68.5–72.6)

72.3 (69.5–72.8)

70.05 (66.1–72.3)

70.1 (68.2–71.8)

71.3 (69.9–72)

67.3 (65.1–69.4)

0.62

0.46

0.19

FFMA, mm (IQR)

15–32

46.65 (41.2–57.3)

51.95 (43.1–56.7)

44.15 (36.9–50.6)

41.7 (35.5–53.7)

54.4 (45.6–60.4)

51.1 (48.5–59.9)

0.70

0.40

0.07

SOFA score (IQR)

4 (4–6)

4 (3–4)

3 (2–4)

4 (3–4)

4 (3–6)

5 (3–6)

0.37

0.29

0.01

Pa0₂/Fi0₂ ratio (IQR)

94 (60–126)

106.5 (77–142)

168 (129–215)

73 (57–130)

93 (73–120)

104 (68–146)

0.80

0.48

0.06